Wed, Jan 28, 2015, 8:12 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

  • fairandhonest2010 fairandhonest2010 May 7, 2013 1:49 PM Flag

    Rare long term growth potential...risk versus reward: tough batle

    This stock is truly interesting.

    It is moved so far so fast that going in is risky. No doubts.

    On the other hand, Eyelea had good sales, growth still there with expanding market, allergan drug delayed and other pipeline agents for growth.

    Tough battle in my mind.

    However, very few growth stocks so would go for it.

    Anyone has other point/counterpoint (not looking for short term play)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A balanced approach#$%$ are you doing on a message board? I would say there is slightly more reason to favor long term considerations. The unofficial position of the FDA is,if we don't outright reject it it will pass some day.Considering strong revenue streams from Eyelea,the delay is not significant. The intellectual portfolio of this company is quite strong. I would feel more comfortable if they split this sucker. You could always sell and hope the day-traders create some ghastly rumor and re-buy lower, Indeed a tough question,

408.00-7.74(-1.86%)Jan 28 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NASDAQWed, Jan 28, 2015 4:00 PM EST
QUALCOMM Incorporated
NASDAQWed, Jan 28, 2015 4:00 PM EST
Core Laboratories NV
NYSEWed, Jan 28, 2015 4:01 PM EST